secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001728117-25-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M
--------------------------------------------------------------------------------

- Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.
- Baseline characteristics align with target: mean 6MWD 376 m, 74% Functional Class III, NT-proBNP 986 ng/L.
- Phase 3 SERANATA study in PH-ILD to begin site activations in Q4 2025 with ~480 patients.
- Cash $257.9M expected to fund operations into H1 2027; Q1 net loss $36.6M ($0.16/share).
- Revenue from Chiesi collaboration $9.9M ($6.6M cost reimbursement); R&D expenses $38.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/0001728117-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001728117-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer